Rosy  Wills

Rosy Wills

Followers 0
Following 0
Please share your specific interest to serve you betterDownload Free Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=197226392This is transforming the practice of hemostasis testing throughout the world.North America and a major part of the Western European region are saturated markets for hemostasis products.The hemostasis analyzers and reagents market in these emerging regions is primarily driven by various economic developments.Moreover, the presence of a large patient population, increasing funding/investment towards the development of hemostasis products, growing focus of both international and domestic players on the Asia-Pacific Coagulation Analyzer Market, and a large number of R activities are the key factors fueling the growth of the Coagulation Analyzer Market in these regions.Coagulation analyzers market is dominated by few major players, with the top 3 players accounting for most of the market share.Prominent players in the coagulation analyzers market include Sysmex Corporation (Japan), Siemens Healthcare (Germany), Roche Diagnostics (Switzerland), Instrumentation Laboratory Werfen Group (U.S.), Helena Laboratories (U.S.), Nihon Kohden Corporation (Nihon Kohden) (Japan), Beckman Coulter, Inc. (U.S.), International Technidyne Corporation (U.S.), Diagnostica Stago, Inc. (France), Alere, Inc. (U.S.), and Thermo Fisher Scientific, Inc. (U.S.), among others.Get Sample Pages: https://www.marketsandmarkets.com/requestsample.asp?id=197226392 In the coagulation analyzers market, leading players are adopting the strategies of new product development, geographic expansion, agreements, acquisitions, and joint ventures.
According to research report the clinical microbiology market is expected to reach USD 4.95 billion by 2023 from USD 3.63 billion in 2018 growing at a CAGR of 6.4% during forecast period.Growth in clinical microbiology market can be attributed to factors such as rising incidence of infectious diseases and growing outbreak of epidemics and increased funding and public-private investments.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219135367Market Size EstimationA detailed market estimation approach was followed to estimate and validate the size of the clinical microbiology market and other dependent submarkets, as mentioned above.The key players in the clinical microbiology market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research.Research methodology includes the study of the annual and quarterly financial reports of the top market players as well as interviews with industry experts for key insights (both quantitative and qualitative trends) on the clinical microbiology market.All percentage shares, splits, and breakdowns were determined by using secondary sources and verified through primary sources.The global clinical microbiology market is segmented by product, disease area, end user, and region.
According to research report the surgical drains market is expected to reach USD 2.18 Billion by 2022 from USD 1.82 Billion in 2017, growing at a CAGR of 3.7%.The growth of this market is mainly driven by the growing geriatric population, increasing number of surgical procedures, and rising awareness programs globally.The surgical drains market is highly competitive with several big and small players.Bard (US), Redax (Italy), Ethicon (US), Stryker (US), Romsons (India), Medtronic (Ireland), Medline Industries (US), Cook Medical (US), Poly Medicure (India), Zimmer Biomet (Indiana), Global Medikit (India), Degania Silicone (Israel), Aspen Surgical (US), National Surgical (Australia), Axiom Medical (US), Péters Surgical (France), Ningbo Luke medical China), Goharshafa (Iran), ARMSTRONG MEDICAL (UK), Angiplast (India), CHIMED (Italy), and pfm medical (Germany).In September 2014, the company formed a new subsidiary—B.This expansion enabled the company to work more closely with customers and Group Purchasing Organizations across the country.
According to research report the global contrast media market is expected to reach USD 8.68 billion by 2027 from USD 4.56 billion in 2018, at a CAGR of 3.9%.The major factors driving the growth of the contrast media/contrast agents market include increasing number of research and funding activities for research of contrast agents and their applications.Please share your specific interest to serve you better: Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=911 North America to dominate the market in 2017 North America, Europe, Asia-Pacific, and Rest of the World (RoW) are the regions considered for a geographic analysis of the global contrast media/contrast agents market.However, the Asia Pacific contrast media/contrast agents market is expected to grow at the highest CAGR in the forecast period.This growth can be attributed to the increasing R investments and favorable demographic scenario in China, rising aging population and cancer incidence in Japan, growing investments in the Indian radiology market, and growing focus of market players & increasing government support in other APAC countries.The prominent players in the global contrast media/contrast agents market include GE Healthcare (US), Bracco Imaging S.p.A. (Bracco) (Italy), Bayer HealthCare (Bayer) (Germany), and Guerbet Group (Guerbet) (France).
According to research report the Cancer Immunotherapy Market is projected to reach USD 119.39 Billion by 2021 from USD 61.97 Billion in 2016, at a CAGR of 14.0%.This report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global cancer immunotherapy market along with the estimates and forecasts of the revenue and market share analysis.Please share your specific interest to serve you better:Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197577894This growth can be attributed to factors such as increasing adoption of target therapy over traditional therapy, emergence of biosimilars, increasing demand for mAbs, high prevalence of cancer.Cancer immunotherapy drugs are designed to alter or boost the body’s natural immune response to fight cancer this market is research-driven with a high degree of dependence on the discovery of molecules that can generate an immune response against various indications.In this report, the global cancer immunotherapy market has been segmented based on type, application, end user, and region.• On the basis of applications, the global cancer immunotherapy market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and others.The lung cancer segment is expected to grow at the highest CAGR during the forecast period.The high growth in this segment can be attributed to the increasing prevalence of this type of cancer and rising demand for advanced treatment options.• On the basis of type, the market has been segmented into monoclonal antibodies, cancer vaccines, checkpoint inhibitors, and immunomodulators.
According to research report the global X-Ray Detectors Market is projected to reach USD 3.8 billion by 2024 from USD 2.8 billion in 2019, at a CAGR of 6.1% during the forecast period.Factors such as growing public and private investments in digital imaging technologies, declining prices and benefits offered by digital detectors, and reimbursement cuts for analog X-rays are driving the growth of the X-ray detectors market.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=7004984 The introduction of wireless X-ray detectors, growing medical tourism in developing countries, and the emerging markets are expected to offer significant growth opportunities for market players in the coming years.However, the high cost of digital X-ray systems is expected to restrain the growth of this market.Based on type, the X-ray detectors market is segmented into flat-panel detectors (FPDs), computed radiography (CR) detectors, charge-coupled device (CCD) detectors, and line-scan detectors.The high growth of this segment is attributed to the advantages of FPD-based portable digital systems, their decreasing prices, and the growing demand for retrofit FPD-based digital X-ray systems.
Factors such as technological advances in medical devices, increasing penetration of smartphones and growing number of smartphone-based healthcare apps compatible with wearable devices, growing preference for wireless connectivity among healthcare providers, and increasing awareness about physical fitness are driving the growth of this market.According to research report the wearable medical devices market is expected to reach USD 14.41 billion by 2022 from USD 6.22 billion in 2017, at a CAGR of 18.3%.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=81753973Based on application, the wearable medical devices market is segmented into remote patient monitoring, home healthcare, and sports & fitness.The sports and fitness segment is expected to register the highest CAGR during the forecast period.The significant growth of segment is owing to factors such as the increasing focus on physical fitness among people to improve the quality of life and growing trend of tracking health progress.Based on type, the wearable medical devices market is segmented into activity monitors, smartwatches, smart clothing, and patches.The activity monitors segment is expected register the highest CAGR during the forecast period.The high growth of this segment can be attributed to factors such as the rising adoption of sedentary and unhealthy lifestyles, rising prevalence of lifestyle diseases, and growing awareness of health and fitness.Based on distribution channel, the wearable medical devices market is segmented into pharmacies, online channel, and hypermarkets.
The report studies the market on the basis of product type, mechanism, application, end user, and region.Market growth is largely driven by the rising global incidence of respiratory diseases, global population, and technological advancements in spirometer devices.According to research report the global Spirometer Market is expected to reach USD 1,047 million by 2023 from USD 655 million in 2018, at a CAGR of 9.8%.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=18015659 The spirometry equipment market is geographically segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW).The high growth in this region can primarily be attributed to the rising geriatric population, high burden of respiratory diseases such as COPD and asthma, growing per capita income, increasing investments in the healthcare industry by key market players, rising demand for cutting-edge technologies, expansion of private-sector hospitals to rural areas in various APAC countries, and the presence of high-growth markets such as Japan, China, India, South Korea, Taiwan, Australia, and Singapore.By product type, the spirometry equipment market is segmented into consumables & accessories, devices, and software.The rising incidence of respiratory diseases and the growing geriatric population are the key factors driving the growth of this product segment.By end user, the spirometry equipment market is segmented into hospitals, clinical laboratories, home care settings, and industrial settings.Based on application, the spirometry equipment market is segmented into COPD, asthma, and other applications.
According to research report the global structural heart devices market is projected to reach USD 15.08 billion by 2023 from USD 9.28 billion in 2018, at a CAGR of 10.2%.Growth in the structural heart devices market is mainly driven by factors such as the rising prevalence of structural heart diseases, regulatory approvals for new and advanced structural heart devices, favourable reimbursement scenario for structural heart procedures & devices, and increasing awareness about structural heart diseases.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=161123753 Players in this market compete to deliver superior and advanced technologies for heart valve repair and replacement.Edwards Lifesciences held the leading position in the global structural heart devices market in 2017 on account of its diverse portfolio of transcatheter and surgical heart valves.The company pursues organic as well as inorganic growth strategies, such as product launches & approvals and acquisitions to further increase its market share and strengthen its foothold in the surgical heart devices market.The unique beating-heart repair procedure for mitral valve patients of Harpoon Medical complements Edwards’ comprehensive portfolio of treatments for structural heart disease and reinforce its commitment to innovation in cardiac surgery.
Factors driving the growth of this market include the increasing incidence of cardiovascular diseases and the launch of innovative and technologically advanced interventional cardiology devices.The interventional cardiology devices market is consolidated in nature due to the presence of a large number of players.The key players in the market are Medtronic (US), Boston Scientific (US), Abbott Laboratories (US), Terumo (Japan), Cordis (US), B.Braun (Germany), C.R.It also distributes its products through direct sales representatives in the US and a combination of direct and indirect sales representatives worldwide.Boston Scientific is a well-known player that develops, manufactures, and markets medical devices that are used in a broad range of interventional medical specialties.In 2015, Boston Scientific partnered with C. R. Bard to distribute its Lutonix 035 Drug-coated Balloon in the US.
Factors such as technological advancements in defibrillators, increasing burden of target diseases, growing focus on providing public-access defibrillators, and rising number of training & awareness programs on defibrillators are driving the growth of the defibrillators market.According to the new market research report defibrillators market is projected to reach USD 10,883.3 million by 2022 from USD 9,323.5 million in 2017 at a CAGR of 3.1%.North America dominated the global defibrillators market in 2017.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=549On the basis of products, the defibrillators market is classified into implantable cardioverter defibrillators (ICDs) and external defibrillators.The ICDs product segment is bifurcated into transvenous implantable cardioverter defibrillators (T-ICDs) and subcutaneous implantable cardioverter defibrillators (S-ICDs).The T-ICDs segment is further classified into single-chamber ICDs, dual-chamber ICDs, and cardiac resynchronization therapy defibrillators (CRT-Ds).The external defibrillators segment is further classified into manual external defibrillators, automated external defibrillators (AEDs), and wearable cardioverter defibrillators (WCDs).Top Market Players – ZOLL Medical (US) held the leadership position in the global external defibrillators market.The company adopted new product launches, agreements, and partnerships as its core business strategies to enhance its share in the global external market.Other prominent players in the global external market included Philips (Netherlands), Physio-Control (US), Cardiac Science (US), Nihon Kohden (Japan), SCHILLER (Switzerland), Mindray Medical (China), Mediana (South Korea), METRAX (Germany), and METsis (Turkey).Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=549Geographic Overview – North America is expected to account for the largest share of the global defibrillators market in 2017, followed by Europe.
According to research report Preclinical Imaging Market is expected to reach USD 910.4 Million by 2021; growing at a CAGR of 6.2% during 2016 to 2021.The Report analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the world (RoW).Over the last two decades, preclinical imaging has witnessed significant importance in the drug discovery and development.Development of technologically advanced multi-modality preclinical imaging systems and their increased adoption in preclinical research studies acted as driving factor for global preclinical imaging market.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=841 Leading Market Players –The key players in the preclinical imaging market focus on various strategies such as product approvals, launches, and enhancements; geographic expansions; partnerships, agreements, and collaborations; and strategic acquisitions in order to increase their market shares in the global preclinical imaging market.Product approvals, launches, and enhancements was the key strategy adopted by major industry players to achieve growth in the preclinical imaging market.This strategy was majorly adopted by PerkinElmer, Inc. (U.S.), Bruker Corporation (U.S.), Mediso Ltd. (Hungary), MILabs B.V. (Netherlands), MR Solutions Ltd. (U.K.), and Aspect Imaging Ltd. (Israel).
According to a new market research report Operating Room Integration Market is projected to grow at a CAGR of 12.4% during the forecast period, to reach USD 1.7 billion by 2024 from USD 1.0 billion in 2019.Factors such as the increasing adoption of minimally invasive surgical procedures, redevelopment projects & funding for improving OR infrastructure, and rising need to curtail healthcare costs are driving the growth of the operating room integration market during the forecast period.Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=160774667 The software segment accounted for the largest share of the operating room integration market, by component, in 2018 The software segment accounted for the largest share of the operating room integration market in 2018.OR integration software helps streamline surgical workflows by enabling seamless communication between different systems as well as ensuring the effective and easier operation of these systems, preferably from a single source.Moreover, operating room integration software helps reduce surgical times, improves coordination between healthcare providers, and improves patient safety.Factors such as the increasing incidence of breast cancer, colorectal cancer, liver cancer, GI disorders, and endocrine disorders as well as the rising number of general surgical procedures performed worldwide are driving the growth of this segment.
According to the new market research report Single-use Bioreactors Market is expected to grow at a CAGR of 21.9% from 2017 to 2022, to reach 2,685.1 Million by 2022 from USD 997.6 Million in 2017.In the current market scenario, there is a growing demand for single-use bioreactor products.The major factors driving the growth of the Single Use Bioreactors include the increasing adoption of SUBs among small companies and startups, reduced automation complexity, ease in cultivating marine organisms, and reduced impact on the environment.Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=49113750  Thermo Fisher Scientific, Inc (U.S.) Held the Leadership Position in the SUB in 2014 Owing to Its Broad Product Portfolio and Strong Brand NameThe Single Use Bioreactors Market is highly consolidated, with the top five players accounting for a share of more than 75%.The major players include Thermo Fischer Scientific, Inc. (U.S.), Sartorius AG (Germany), Merck KGaA (Germany), GE Healthcare (U.S.), and Pall Corporation (U.S.).Thermo Fisher Scientific, Inc. will hold the leadership position in the Single Use Bioreactors Market in 2014.The company has an extensive product portfolio, including bioreactors such as open architecture bioreactor systems, turnkey bioreactor systems, and bioreactor accessories.The company has a good reputation and a strong customer base for its SUBs.
The major factors driving the growth of the contrast media/contrast agents market include increasing number of research and funding activities for research of contrast agents and their applications.According to research report the global contrast media market is expected to reach USD 5.53 billion by 2022 from an estimated USD 4.57 billion in 2017, growing at a CAGR of 3.9% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=911 • By type, the iodinated contrast media segment is expected to account for the largest share of the market in 2017• By modality, the X-ray/CT segment is expected to account for the largest share of the contrast media market in 2017• North America to dominate the market in 2017North America, Europe, Asia-Pacific, and Rest of the World (RoW) are the regions considered for a geographic analysis of the global contrast media/contrast agents’ market.North American contrast media/contrast agents’ market is expected to account for the largest share of the global contrast media/contrast agents’ market.GE Healthcare held the first position in the global contrast media market in 2017.The firm has a strong customer base in approximately 175 countries, primarily operating in North America, Europe, the Pacific Basin, the Americas, and the Middle East & Africa.Some subsidiaries of the firm include GE Healthcare USA Holdings, Inc., GE Healthcare Ltd. (Japan), GE Healthcare Biosciences AB (US), and GE Healthcare AS (Norway).GE Healthcare received the Norwegian Medicines Agency's (NOMA) approval for SONAZOID, a contrast agent used in ultrasound imaging of focal liver lesions.
The global prosthetic heart valves market covers the artificial heart valves which are implanted in the hearts of patients suffering from heart valve disease (HVD).This market is expected to reach USD 8.86 billion by 2022 from USD 4.84 billion in 2017, at a CAGR of 12.9% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=245407958 Globally, the prosthetic heart valves market is witnessing growth due to factors such as rising geriatric population and the subsequent growth in the prevalence of heart valve disease (HVD), regulatory approvals for new and advanced prosthetic heart valves, increasing government funding for heart valve research, rising awareness about HVD, and favorable reimbursement scenario for prosthetic heart valves.On the other hand, the high cost of transcatheter aortic valve replacement (TAVR) procedures and the availability of alternative methods for treating HVD are expected to restrain market growth to a certain extent.Based on the type of valves, the prosthetic heart valves market is segmented into transcatheter heart valves, tissue heart valves, and mechanical heart valves.The transcatheter heart valves segment is expected to continue to dominate the global prosthetic heart valves market in 2022.The large share of this segment can be attributed to the rising prevalence of aortic stenosis, increasing pool of patients owing to approvals for extended valve indications, and technological advancements.
According to research report the global X-Ray Detector Market is projected to reach USD 3.8 billion by 2024 from USD 2.8 billion in 2019, at a CAGR of 6.1% during the forecast period.Market growth is mainly driven by the growing public and private investments in digital imaging technologies, declining prices and benefits offered by digital detectors, and reimbursement cuts for analog X-rays.The introduction of wireless X-ray detectors, growing medical tourism in developing countries, and the emerging markets are expected to provide a wide range of growth opportunities for players in the market.The X-ray detectors market is highly consolidated in nature with several big and emerging players.Prominent players in this market include Varex Imaging Corporation (US), Thales Group (France), Canon, Inc. (Japan), Konica Minolta, Inc. (Japan), Teledyne DALSA Inc. (US), Fujifilm Holding Corporation (Japan), Agfa-Gevaert Group (Belgium), Carestream Health (US), Vieworks Co., Ltd (South Korea), Hamamatsu Photonics K.K.The company has managed to create a unique identity in this market due to its robust product portfolio and large geographic presence.
Market growth can be attributed to increasing obese population, increasing number of bariatric surgeries, growing adoption of online weight loss and weight management programs, rise in disposable income in developing economies, sedentary lifestyle, and increasing government initiatives for creating awareness among obese populations.What the Market Looks Like?According to the new market research report the weight loss and weight management market is expected to reach USD 245.51 billion by 2022 from USD 175.94 billion in 2017, at a CAGR of 6.9%.The market in Asia is expected to grow at the highest CAGR during the forecast period.Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1152  Major Market DevelopmentsIn 2017, Conyers Park and Atkins combined to form a new holding company, The Simply Good Foods Company.This company is expected to expand its platform through investment opportunities in the snacking space and broader food category.In 2017, Brunswick partnered with VirZOOM to launch the VirZOOM solution, which is expected to transform Life Fitness's Discover SE3 bikes into aVirtual Reality In 2016, Brunswick acquired Indoor Cycling Group (ICG).The acquisition expanded Brunswick’s portfolio of fitness products.In 2016, Atkins partnered with Chef'd to launch a low carb meal solution for health-conscious consumersProduct launches accounted for the largest share of the overall growth strategies mapped from 2014–2017.Some of the leading players who adopted this strategy are Atkins Nutritionals (US), Brunswick (US), Nutrisystem (US), Weight Watchers (US), Amer Sports (Finland), Herbalife (US), and Johnson Health Technology (Taiwan).Prominent players in the weight loss and weight management market, by diet, include Atkins Nutritionals, Inc. (Atkins) (US), Herbalife Ltd. (Herbalife) (US), Nutrisystem Ltd. (Nutrisystem) (US), and Kellogg Company (Kellogg) (US).Ethicon, Inc. (Ethicon) (US), Covidien, plc.(Covidien) (US), Apollo Endosurgery (US), and Olympus Corporation (Olympus) (Japan) are some prominent players in the surgical equipment market, while Brunswick Corporation (Brunswick) (US), Amer Sports (Finland), Johnson Health Technology, Ltd. (Johnson Health Tech) (Taiwan), Cybex International (Cybex) (US), and Technogym SpA (Technogym) (Italy) operate in the fitness equipment segment.Read more: https://www.marketsandmarkets.com/PressReleases/weight-loss-obesity-management.aspMarket DynamicsFitness Centres and Health ClubsFitness centers offer group exercises, personalized programs, timely body composition analyses, water workouts, yoga sessions, spinning sessions, and cardiovascular exercises for weight management and physical health and fitness.
According to the new market research report immunoassays market is expected to reach USD 34.44 billion by 2027 from USD 20.19 billion in 2018, at a CAGR of 6.1%.The increasing incidence of chronic and infectious diseases, technological advancements in immunoassay instruments and introduction of novel automated systems, and growth in the biotechnology and biopharmaceutical industries are some the major factors driving the growth of this market.Read More: https://www.marketsandmarkets.com/PressReleases/immunoassay.asp By product and service, the reagents and kits segment commanded the largest share of the market in 2017On the basis product and service, this market is classified into reagents and kits, analyzers, and software and services.In 2017, the reagents and kits segment accounted for the largest share of the immunoassays market.The large share of this segment can primarily be attributed to the requirement of the repeat purchase of kits and reagents, coupled with the increasing number of immunoassay tests being performed across the globe as a result of the rising incidence of chronic and infectious diseases.The chemiluminescence immunoassays (CLIAs) segment led the immunoassays market in 2017By platform, this market is classified into CLIAs, radioimmunoassays (RIAs), colorimetric immunoassays (CIs), fluorescence immunoassays (FIAs), and other platforms.The large share of this segment can primarily be attributed to the low cost and high sensitivity of CLIA-based tests.By technology, the enzyme-linked immunosorbent assays (ELISA) segment accounted for the largest share of the market in 2017On the basis of technology, the immunoassays market is segmented into ELISA, rapid tests, western blotting, enzyme-linked immunospot (ELISPOT), immuno-PCR, and other immunoassay technologies.The large share of this segment can primarily be attributed to the increasing use of immunoassay tests in cancer, infectious diseases, and therapeutic drug level monitoring.
Over the last two decades, preclinical imaging has witnessed significant importance in the drug discovery and development.Development of technologically advanced multi-modality preclinical imaging systems and their increased adoption in preclinical research studies acted as driving factor for global preclinical imaging market.Market Overview -According to research report preclinical imaging market is expected to reach USD 910.4 Million by 2021; growing at a CAGR of 6.2% during 2016 to 2021.The Report analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the world (RoW).Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=841Geographical Overview -North America (except Mexico) and a major part of the European region are mature markets for preclinical imaging systems and reagents.However, developing regions such as Asia-Pacific (including China, South Korea, and Taiwan) and Latin America (especially Brazil) are expected to become new revenue-generating markets for players dealing with preclinical imaging systems and reagents.The high growth opportunities in the Asia-Pacific region is attributed to the rising number of CROs offering preclinical research studies, increasing outsourcing of preclinical research by global pharma companies to developing Asian countries (owing to low cost of research), and increasing government funding for pharmaceutical R activities in emerging Asia-Pacific countries.In the Asia-Pacific region, the preclinical imaging market in China is estimated to grow at the highest rate in the next five years.Increased government investments towards the development of country’s pharmaceutical industry are leading to the growth in the number of preclinical research studies in China.
More

Top